Vol 8, Supp. A (2017)
Case report
Published online: 2017-12-21
Leczenie pomalidomidem chorego na szpiczaka plazmocytowego po przeszczepieniu allogenicznych krwiotwórczych komórek macierzystych od dawcy niespokrewnionego
Abstract
The case report presents IgA plasma cell myeloma patient treated with chemotherapy, botrezomib,
autologous hematopoietic stem cell transplantation, lenalidomide, unrelated donor allogeneic hematopoietic stem cell transplantation and finally pomalidomide (POM). In spite of lack of deep,
long-term response after any of the therapies, the combined treatment using all modalities currently
available in Poland led to prolonged survival of the patient. Of note, POM employed as sixth-line
therapy showed good efficacy and relatively few side effects over a 27-cycle treatment period.
Keywords: plasma cell myelomatreatmentpomalidomid